Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(transdermal infusion system)
300 results
  • Clonidine as a strategy for discontinuing dexmedetomidine sedation in critically ill patients: A narrative review. [Journal Article]
    Am J Health Syst Pharm. 2020 Mar 24; 77(7):515-522.Glaess SS, Attridge RL, Christina Gutierrez G
  • CONCLUSIONS: A MEDLINE literature search was performed to identify original research articles describing DWS and/or transitioning from dexmedetomidine to clonidine for the purpose of weaning patients from sedation with dexmedetomidine. Four case reports describing DWS, 3 case reports describing the use of clonidine to treat DWS, and 3 observational studies describing the use of clonidine to facilitate dexmedetomidine weaning were identified. The incidence of and risk factors for DWS are unknown; factors including patient age and dexmedetomidine infusion rate, loading dose, and discontinuation strategy have inconsistent associations with DWS. All cases of DWS have been associated with infusion durations greater than 72 hours. While there are limited data describing clonidine use for the treatment of dexmedetomidine withdrawal, clonidine appears to be beneficial for dexmedetomidine weaning and its use for that purpose has been well described. Clonidine dosages that have been assessed for discontinuing dexmedetomidine vary from 0.1 to 0.3 mg orally or enterally every 6 to 8 hours; one study assessed use of transdermal clonidine (100 µg/24 h patch). Patients with extensive cardiac comorbidities may be more susceptible to adverse effects of clonidine, which may limit the drug's use for DWS intervention.Despite limited supportive data, clonidine provides a promising option for sedation management in adult ICU patients, with successful transitions from dexmedetomidine reported within 24 hours after clonidine initiation.
  • Ethosomal Gel for Improving Transdermal Delivery of Thymosin β-4. [Journal Article]
    Int J Nanomedicine. 2019; 14:9275-9284.Fu X, Shi Y, … Lin G
  • CONCLUSIONS: Hence, we provide a possible good design for ethosomal gel system that can load macromolecular protein peptide drugs to achieve transdermal drug administration, promoting the percutaneous absorption of the drug and improving the effect.
  • Insulin Therapy: Future Perspectives. [Review]
    Am J Ther. 2020 Jan/Feb; 27(1):e121-e132.Cernea S, Raz I
  • CONCLUSIONS: The improved insulin formulations, newer delivery methods/routes, and digital technologies are rapidly becoming effective and have great potential to improve metabolic control as well as other outcomes, including quality of life of persons living with diabetes mellitus.
  • Snake fang-inspired stamping patch for transdermal delivery of liquid formulations. [Journal Article]
    Sci Transl Med. 2019 07 31; 11(503)Bae WG, Ko H, … Jeong HE
  • A flexible microneedle patch that can transdermally deliver liquid-phase therapeutics would enable direct use of existing, approved drugs and vaccines, which are mostly in liquid form, without the need for additional drug solidification, efficacy verification, and subsequent approval. Specialized dissolving or coated microneedle patches that deliver reformulated, solidified therapeutics have made…
  • Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease. [Review]
    J Parkinsons Dis. 2018; 8(s1):S65-S72.van Wamelen DJ, Grigoriou S, … Odin P
  • Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, non-continuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental obse…
  • Advances in transdermal insulin delivery. [Review]
    Adv Drug Deliv Rev. 2019 01 15; 139:51-70.Zhang Y, Yu J, … Gu Z
  • Insulin therapy is necessary to regulate blood glucose levels for people with type 1 diabetes and commonly used in advanced type 2 diabetes. Although subcutaneous insulin administration via hypodermic injection or pump-mediated infusion is the standard route of insulin delivery, it may be associated with pain, needle phobia, and decreased adherence, as well as the risk of infection. Therefore, tr…
  • Insulin Pumping Patches: Emerging Insulin Delivery Systems. [Introductory Journal Article]
    J Diabetes Sci Technol. 2019 01; 13(1):8-10.Thompson B, Cook CB
  • In this special section of JDST, patch-pump delivery systems ("patch pumps") are discussed. Patch pumps are novel insulin delivery systems that have emerged on the market; offering flexible insulin delivery options. These systems offer several advantages over conventional insulin pump delivery systems and are gaining popularity. Patch pumps are free of tubing, small, and lightweight. In this spec…
  • Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review. [Review]
    Am J Clin Dermatol. 2019 Feb; 20(1):97-114.Jedlowski PM, Te CH, … Fazel MT
  • Diabetes mellitus is one of the most prevalent chronic diseases in the USA. If uncontrolled, diabetes can lead to devastating complications. Diabetes medications and medical devices largely contribute to the significant financial expense that the disease inflicts on affected individuals and society. Alongside significant economic burden, there are numerous cutaneous adverse effects associated wit…
  • Intrathecal Pump Implantation in the Cisterna Magna for Treating Intractable Cancer Pain. [Case Reports]
    Case Rep Anesthesiol. 2018; 2018:5287150.Lou Y, Rao Y, Feng Z
  • A 54-year-old male patient with postoperative axillary lymph node, intrapulmonary, intracranial, and cervical spine metastases of left liver cancer was suffering from severe, persistent, and pricking pain in the right dorsal shoulder and right arm since 3 months. The drug dose of the fentanyl transdermal patch was gradually increased after admission and an adjuvant analgesic was also included, bu…
  • Patch Pumps: Are They All the Same? [Review]
    J Diabetes Sci Technol. 2019 01; 13(1):34-40.Heinemann L, Waldenmaier D, … Freckmann G
  • Insulin pumps are used by a steadily increasing number of patients with diabetes. Avoiding certain disadvantages of conventional pumps (ie, the insulin infusion set) might make pump therapy even more attractive. Patch pumps are usually attached by means of an adhesive layer to the skin and have several additional advantages (smaller, more discrete, easier to use, and cheaper than conventional ins…
  • Patch Pumps for Insulin. [Review]
    J Diabetes Sci Technol. 2019 01; 13(1):27-33.Ginsberg BH
  • Newly developed patch pumps are starting to occupy a noticeable fraction of the insulin delivery market. New entrants, using novel technologies, promise accurate, flexible insulin delivery at lower costs. In the section, we review the currently available devices, discuss some of the devices on the horizon, and speculate about some fascinating new approaches. In this first article, we provide an o…
  • Transdermal rotigotine patch in Parkinson's disease with a history of intestinal operation. [Case Reports]
    BMJ Case Rep. 2018 Jun 15; 2018Ogawa T, Oyama G, Hattori N
  • A 42-year-old Japanese man with a history of small intestine resection and familial Mediterranean fever was referred to our hospital for a second opinion on parkinsonism. At the age of 35, the patient attended a hospital due to impaired left-hand movement and resting tremor. He was previously diagnosed with multiple system atrophy based on the lack of effectiveness of levodopa treatment. With sus…
  • Glucose-Responsive Microneedle Patches for Diabetes Treatment. [Review]
    J Diabetes Sci Technol. 2019 01; 13(1):41-48.Chen G, Yu J, Gu Z
  • Antidiabetic therapeutics, including insulin as well as glucagon-like peptide 1 (GLP-1) and its analogs, are essential for people with diabetes to regulate their blood glucose levels. Nevertheless, conventional treatments based on hypodermic administration is commonly associated with poor blood glucose control, a lack of patient compliance, and a high risk of hypoglycemia. Closed-loop drug delive…
  • Current development in the formulations of non-injection administration of paclitaxel. [Review]
    Int J Pharm. 2018 May 05; 542(1-2):242-252.Du X, Khan AR, … Zhai G
  • Paclitaxel (PTX) belongs to a class of taxane anti-tumor drug used for the clinic treatment of breast cancer, ovarian cancer, non-small-cell lung cancer, and so on. PTX has poor water solubility and oral bioavailability. It is generally administered via intravenous (i.v.) infusion. Traditional PTX injectable preparations contain Cremophor-EL and ethanol to improve its solubility, which would resu…
  • MEMS devices for drug delivery. [Review]
    Adv Drug Deliv Rev. 2018 03 15; 128:132-147.Lee HJ, Choi N, … Cho IJ
  • Novel drug delivery systems based on microtechnology have advanced tremendously, but yet face some technological and societal hurdles to fully achieve their potential. The novel drug delivery systems aim to deliver drugs in a spatiotemporal- and dosage-controlled manner with a goal to address the unmet medical needs from oral delivery and hypodermic injection. The unmet needs include effective de…
  • Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future. [Review]
    NPJ Parkinsons Dis. 2016; 2:16023.Ray Chaudhuri K, Qamar MA, … Jenner P
  • Dysfunction of the gastrointestinal tract has now been recognized to affect all stages of Parkinson's disease (PD). The consequences lead to problems with absorption of oral medication, erratic treatment response, as well as silent aspiration, which is one of the key risk factors in developing pneumonia. The issue is further complicated by other gut abnormalities, such as small intestinal bacteri…
  • Device-Aided Treatment Strategies in Advanced Parkinson's Disease. [Review]
    Int Rev Neurobiol. 2017; 132:453-474.Timpka J, Nitu B, … Antonini A
  • With peroral levodopa treatment, a majority of patients develop motor fluctuations and dyskinesia already within a few years of therapy. Device-aided Parkinson (PD) therapies refer to deep brain stimulation (DBS), levodopa-carbidopa intestinal gel infusion (LCIG), and subcutaneous infusion of the dopamine agonist apomorphine and represent effective strategies counteracting motor fluctuations and …
New Search Next